Refer to the incident report submitted to (b)(6), competent authority.The final report is summarized below: the manufacturer's device analysis results: this (b)(6) year old critically ill female patient had a prior history of chronic ischemic heart disease and tight aortic stenosis.Prior to hemolung therapy, the patient underwent a coronary artery bypass graft and received a biologic aortic valve prosthesis.Two days later her respiratory failure was worsening.She became hemodynamically unstable and her acute respiratory distress syndrome (ards) was progressing making oxygenation and co2 removal difficult to achieve on invasive mechanical ventilation.Hemolung therapy was agreed upon by the patient's son to address her co2 retention.The physician followed standard cannulation procedures but the guidewire was advanced into the superior vena cava where it penetrated the vessel in a medial and ventral direction into the hilus of the right lung and into the proximal parts of the middle and inferior lung lobes.At autopsy, profuse amounts of blood were found in the trachea, right hilum and proximal parts of the mid and superior lobe.This hemorrhagic event caused acute circulatory collapse, asystole, and death.This event is a known risk of the cannulation procedure and is included in alung's risk documentation.Following the review of the physician's report and autopsy report, alung has determined that while this is a known complication, suboptimal catheter placement technique cannot be ruled out.This is our final report.
|